微生态制剂治疗透析性便秘52例临床观察

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (0 KB) HTML (41 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo exploring methods for the treatment of long-term dialysis patients with constipation.Methods52 cases of patients with chronic kidney disease(CKD)5 were selected,who were taken with maintenance hemodialysis treatment in our hospital from Delember 2015 to Delember 2016,were treated with oral bifidobacterium triple viable enteric capsules for 4 weeks,the stool frequency,character of stool integral,and defecate difficulty were compared between before and after treatment.ResultsAfter treatment for 2 weeks and 4 weeks compared with before treatment,the patient′s stool frequency and defecate difficulty points were obviously increased,the defecate difficulty points were significantly dropped,the difference was statistically significant(P<0.05).But 4 weeks after treatment compared with 2 weeks after treatment,only defecate difficulty point was statistically significant(P<0.05).ConclusionIntestine microecologic agents can treat dialysis patients with chronic constipation safly and effectively.

Key words： Hemodialysis Constipation Intestine microecologic agents

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Yang
	SHEN Jiang-shan
	YIN Jin-feng

Cite this article:

ZHOU Yang,SHEN Jiang-shan,YIN Jin-feng. Clinical observation of intestine microecologic agents in the treatment of dialysis constipation[J]. 中国当代医药, 2017, 24(14): 33-36.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I14/33

[1]	王海燕.肾脏病学[M].3版.北京：人民卫生出版社，2008：1815-1816.
[2]	Venetia G,Li LN,Bordeianou.Surgical management of severe constipation due to slow transit and obstructed defecation syndrome[J].Semi Colon Rect Surg，2016，27：28-32.
[3]	季洪赞，吴琳，吴晓尉，等.强化细则罗马Ⅲ标准的一般疗法辅助普芦卡必利对老年功能性便秘的临床疗效观察[J].临床消化病杂志，2016，28（6）：346-350.
[4]	卫生部.中药新药临床研究指导原则[M]．北京:中国医药科技出版社，2002：127-379．
[5]	袁庆延，丁曙晴，谭妍妍，等.慢性便秘临床疗效评价的现状[J].世界华人消化杂志，2015，23（34）：5566-5572.
[6]	杨龙.长期透析患者便秘的治疗探讨[J].透析与人工器官，2002，13（2）：38-40.
[7]	张秋瓒，杨华.功能性便秘的药物治疗[J].中国全科医学，2005，8（2）：129-130.
[8]	刘洋.慢性便秘的病因与治疗研究进展[J].现代医药卫生，2014，30（10）：1496-1499.
[9]	Tonini M,De Ponti F，Di Nucci A，et al.Review article：cardiac adverse effects of gastrointestinal prokinetics[J].Aliment Pharmacol Ther，1999，13（12）：1585-1591.
[10]	Michele PLG,Michele C,Lorenza P,et al.Gastrointestinal neuromuscular apparatus:Anunderestimated target of gut microbiota[J].World J Gastroenterol，2016，22（45）：9871-9879.
[11]	王佩佩，罗雯，禹铮，等.慢性便秘的研究进展[J].中国全科医学，2017，20（3）：370-374.
[12]	刘巧云，张松，曹海超，等.粪菌移植对顽固性功能性便秘患者临床疗效及生活质量的影响[J].中华消化病与影像杂志（电子版），2017，17（1）：4-8.
[13]	Ning FY.Protective effect of Bifid Triple Viable Capsules on intestinal mucosal barrier function in patients with chemotherapy-induced diarrhea[J].Chin J Microecol，2014，26（7）：812-814.
[14]	Sen Q，Yang RW.Curative effect and security of Bifid Triple Viable Powder in treatment of antibiotic associated diarrhea in children[J].Chin J Microecol，2014，26（11）：1305-1307.
[15]	Chmielewska A，Szajewska H．Systematic review of randomised controlled trials:probiotics for functional constipation[J].World J Gastroenterol，2010，16（1）：69-75.
[16]	毛靖伟，王英德．肠黏膜屏障在炎症性肠病中作用机制的研究[J]．世界华人消化杂，2010，18（7）：695-698．
[17]	孙劦义，蒋先洪.尿毒症患者肠道菌群失调与微炎症状态的关系[J].中国医学前沿杂志（电子版），2015，7（5）：96-99.
[18]	魏萌，蒋红利，王志刚，等.尿毒症大鼠肠道菌群失调及其与微炎症状态的相关性[J].西安交通大学学报（医学版），2013，34（3）：341-345.
[19]	Reuter G.The Lactobacillus and Bifidobacterium microflora of the human intestine：composition and succession[J].Curr Issues Intest Microbiol，2001，（2）：43-53.
[20]	Rada V，Vlková E，Nevoral J，et al.Comparison of bacterial flora and enzymatic activity in faeces of infants and calves[J]. FEMS Microbiol Lett，2006，258：25-28.
[21]	Begley M，Chill CG，Gahan.Bile salt hydrolase activity in probiotics[J].Appl Environ Microbiol，2006，72（3）：1729-1738.
[22]	李迎雪，王立生.双歧杆菌抗肿瘤信号机制的研究[J].中国微生态学杂志，2006，18（6）：497-498.
[23]	Yamazaki S，Kaneko T，Taketomo N，et al．2-Amino-3-carboxy1，4-naphthoquinone affects the end-product profile of bifidobacteria through the mediated oxidation of NAD（P）H[J].Appl Microbiol Biotechnol，2002，59（1）：72.
[24]	Kwon A，Jo SH，IM HJ，et al．Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy[J]．J Thromb Thrombol，2011，32（4）：467-473．
[25]	杨敏.促动力药配伍金双歧治疗小儿功能性便秘53例临床观察[J].长治医学院学报，2004，18（4）：294-295.
[26]	王红兵.润肠通便汤合金双歧治疗功能性便秘62例[J].河南中医学院学报，2006，21（2）：60-61.
[27]	武文斌，陈宏书.不同血液净化方式对尿毒症患者血清脂蛋白和炎性因子的影响[J].中国当代医药，2012，19（36）：60-63.